Lantern Pharma's HARMONIC™ Trial Shows 86% Clinical Benefit In Never Smokers With Advanced NSCLC

Lantern Pharma, a pioneering AI-driven company in oncology drug discovery and development, has reported promising preliminary results from the initial patient group in their ongoing HARMONIC™ phase 2 clinical trial. This trial focuses on Lantern’s new drug candidate, LP-300, used in combination with pemetrexed and carboplatin, targeting never smokers with advanced non-small cell lung cancer (NSCLC) who have seen disease progression after tyrosine kinase inhibitor (TKI) treatment. The development of LP-300 has been significantly supported by Lantern’s AI platform, RADR®, which assists in validating mechanisms and identifying targeted patient populations. RADR® leverages over 100 billion data points to advance Lantern’s portfolio and collaborate on development initiatives.

In the initial safety lead-in phase of the Phase 2 HARMONIC™ study, 7 patients received the LP-300 drug candidate in combination with intravenous pemetrexed and carboplatin. Preliminary findings from this 7-patient cohort indicated that the safety profiles were predictable and consistent with those of the chemotherapy regimen alone. Importantly, there were no dose-limiting toxicities or treatment-related discontinuations. The most commonly observed adverse events included decreases in white blood cell and platelet counts (thrombocytopenia).

The randomization and expansion phase of the HARMONIC™ study is currently underway, evaluating the Progression Free Survival (PFS) and Overall Survival (OS) of patients treated with pemetrexed and carboplatin, with or without LP-300. Details of the full study design are available on clinicaltrials.gov.

For never smokers with NSCLC who experience progression on tyrosine kinase inhibitors (TKIs), treatment with checkpoint modulator immunotherapy is often not an option. Consequently, these patients typically face poor outcomes when treated with the standard chemotherapy regimen of pemetrexed and carboplatin alone. This underscores a critical need for innovative treatment options that do not introduce overlapping or additional toxicities to the standard chemotherapy doublet.

Janakiraman Subramanian, MD and Director of Thoracic Oncology at Inova Schar Cancer Institute, said that “Preliminary results indicate that this LP-300 triplet regimen is active against advanced NSCLC with actionable alterations and there were no unexpected adverse events. Also, the early Harmonic patient data indicates that the adverse events appear to be primarily due to chemotherapy and not the study drug.”